These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 23524968)
1. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. Guo S; Casu C; Gardenghi S; Booten S; Aghajan M; Peralta R; Watt A; Freier S; Monia BP; Rivella S J Clin Invest; 2013 Apr; 123(4):1531-41. PubMed ID: 23524968 [TBL] [Abstract][Full Text] [Related]
2. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. Schmidt PJ; Toudjarska I; Sendamarai AK; Racie T; Milstein S; Bettencourt BR; Hettinger J; Bumcrot D; Fleming MD Blood; 2013 Feb; 121(7):1200-8. PubMed ID: 23223430 [TBL] [Abstract][Full Text] [Related]
3. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia. Nai A; Pagani A; Mandelli G; Lidonnici MR; Silvestri L; Ferrari G; Camaschella C Blood; 2012 May; 119(21):5021-9. PubMed ID: 22490684 [TBL] [Abstract][Full Text] [Related]
4. Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice. Finberg KE; Whittlesey RL; Andrews NC Blood; 2011 Apr; 117(17):4590-9. PubMed ID: 21355094 [TBL] [Abstract][Full Text] [Related]
5. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity. Casu C; Pettinato M; Liu A; Aghajan M; Lo Presti V; Lidonnici MR; Munoz KA; O'Hara E; Olivari V; Di Modica SM; Booten S; Guo S; Neil G; Miari R; Shapir N; Zafir-Lavie I; Domev H; Ferrari G; Sitara D; Nai A; Rivella S Blood; 2020 Oct; 136(17):1968-1979. PubMed ID: 32556142 [TBL] [Abstract][Full Text] [Related]
6. Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model. Schmidt PJ; Fitzgerald K; Butler JS; Fleming MD Am J Hematol; 2021 Feb; 96(2):251-257. PubMed ID: 33180328 [TBL] [Abstract][Full Text] [Related]
7. Hepcidin and Hfe in iron overload in beta-thalassemia. Gardenghi S; Ramos P; Follenzi A; Rao N; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S Ann N Y Acad Sci; 2010 Aug; 1202():221-5. PubMed ID: 20712796 [TBL] [Abstract][Full Text] [Related]
8. Hemochromatosis and pregnancy: iron stores in the Hfe-/- mouse are not reduced by multiple pregnancies. Neves JV; Olsson IA; Porto G; Rodrigues PN Am J Physiol Gastrointest Liver Physiol; 2010 Apr; 298(4):G525-9. PubMed ID: 20110460 [TBL] [Abstract][Full Text] [Related]
9. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nicolas G; Viatte L; Lou DQ; Bennoun M; Beaumont C; Kahn A; Andrews NC; Vaulont S Nat Genet; 2003 May; 34(1):97-101. PubMed ID: 12704388 [TBL] [Abstract][Full Text] [Related]
10. Enhanced erythropoiesis in Hfe-KO mice indicates a role for Hfe in the modulation of erythroid iron homeostasis. Ramos P; Guy E; Chen N; Proenca CC; Gardenghi S; Casu C; Follenzi A; Van Rooijen N; Grady RW; de Sousa M; Rivella S Blood; 2011 Jan; 117(4):1379-89. PubMed ID: 21059897 [TBL] [Abstract][Full Text] [Related]
11. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Gao J; Chen J; Kramer M; Tsukamoto H; Zhang AS; Enns CA Cell Metab; 2009 Mar; 9(3):217-27. PubMed ID: 19254567 [TBL] [Abstract][Full Text] [Related]
12. Bone morphogenetic protein signaling is impaired in an HFE knockout mouse model of hemochromatosis. Corradini E; Garuti C; Montosi G; Ventura P; Andriopoulos B; Lin HY; Pietrangelo A; Babitt JL Gastroenterology; 2009 Oct; 137(4):1489-97. PubMed ID: 19591830 [TBL] [Abstract][Full Text] [Related]
13. Hepcidin expression in iron overload diseases is variably modulated by circulating factors. Ravasi G; Pelucchi S; Trombini P; Mariani R; Tomosugi N; Modignani GL; Pozzi M; Nemeth E; Ganz T; Hayashi H; Barisani D; Piperno A PLoS One; 2012; 7(5):e36425. PubMed ID: 22586470 [TBL] [Abstract][Full Text] [Related]
14. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia. Vadolas J; Ng GZ; Kysenius K; Crouch PJ; Dames S; Eisermann M; Nualkaew T; Vilcassim S; Schaeper U; Grigoriadis G Br J Haematol; 2021 Jul; 194(1):200-210. PubMed ID: 33942901 [TBL] [Abstract][Full Text] [Related]
15. Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Finberg KE; Whittlesey RL; Fleming MD; Andrews NC Blood; 2010 May; 115(18):3817-26. PubMed ID: 20200349 [TBL] [Abstract][Full Text] [Related]
16. Reversal of hemochromatosis by apotransferrin in non-transfused and transfused Hbbth3/+ (heterozygous B1/B2 globin gene deletion) mice. Gelderman MP; Baek JH; Yalamanoglu A; Puglia M; Vallelian F; Burla B; Vostal J; Schaer DJ; Buehler PW Haematologica; 2015 May; 100(5):611-22. PubMed ID: 25616571 [TBL] [Abstract][Full Text] [Related]
17. Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations. Flanagan JM; Peng H; Beutler E Alcohol Clin Exp Res; 2007 Jan; 31(1):138-43. PubMed ID: 17207112 [TBL] [Abstract][Full Text] [Related]